Vivo Infusion, backed by InTandem Capital Partners, announced on July 9 that it acquired Infusion Associates for an undisclosed price.
Founded in 2001, Infusion Associates is a provider of infusion services across the Midwestern United States. The company specializes in long-term treatment of chronic health conditions across a range of therapeutic areas including neurology, gastroenterology, rheumatology and immunology.
Vivo Infusion provides infusion and injection care for patients suffering from compromised immune systems, infectious diseases and other medical conditions. Vivo serves communities in Colorado, Florida, Ohio, Oklahoma, Pennsylvania, New Jersey and Texas with plans to expand to additional states. Private equity firm InTandem Capital Partners created Vivo Infusion by merging MPP Infusion Centers and ID Consultants in March 2022.
With this acquisition, Vivo Infusion will manage nearly 80 ambulatory infusion centers across 15 states. TripleTree served as the exclusive financial advisor to Infusion Associates for this transaction.
“We are thrilled to welcome the Infusion Associates team to the Vivo family,” said Chris Reef, Chief Executive Officer of Vivo Infusion. “Infusion Associates brings several unique capabilities to Vivo’s growing business which will continue to strengthen our relationships with our patients, payors and pharma partners. We are delighted to partner with the entire team.”
According to data captured in the LevinPro HC database, this acquisition represents the eighth infusion services transaction of the year. This is a significant increase from the year before when four infusion services transactions were reported between January 1, 2023, and July 9, 2023.
